Active, Not RecruitingPhase 4ketamine
Ketamine + Cognitive Training for Suicidality in the Medical Setting
Sponsored by Rebecca Price
NCT ID
NCT04578938
Target Enrollment
200 participants
Start Date
2021-03-15
Est. Completion
2026-12-02
About This Study
This project seeks to identify the acute and longer-term impact of a single dose of intravenous ketamine among suicidal patients referred for psychiatric consultation/liaison in the medical inpatient setting. The investigators will then test whether ketamine's rapid effects can be extended by introducing helpful information delivered by a computer-based training protocol. This work could ultimately lead to the ability to treat suicidality more efficiently and with broader dissemination by rapidly priming the brain for helpful forms of learning.
Conditions Studied
Interventions
- •Intravenous ketamine
- •Cognitive training
- •Sham Training
Eligibility
Age:18 Years - 70 Years
Healthy Volunteers:No
View full eligibility criteria
Inclusion Criteria: Participants who receive ketamine will: 1. be between the ages of 18 and 70 years 2. be a medical inpatient referred for psychiatric consultation/liaison due to suicidality and determined by psychiatric C/L to require follow-up psychiatric care (inpatient or outpatient) 3. possess a level of judgment and understanding sufficient to agree to all procedures required by the protocol and must sign an informed consent document 4. be deemed an appropriate and reasonable medical candidate for intravenous ketamine by a physician authorized to prescribe medication to the patient during inpatient hospitalization Exclusion Criteria: 1. Presence of current/acute psychosis with significant thought disruption, mania, delirium, or dementia, or a diagnosis of developmental disorder with significant language and/or intellectual impairment 2. Mini-Mental State Exam (MMSE) \< 21 3. Current pregnancy or breastfeeding 4. Reading level \<5th grade as per WRAT-3 reading subtest AND patient declines to have all questionnaire items and task instructions read aloud to them at all assessment points 5. Past intolerance or hypersensitivity to ketamine or esketamine 6. Patients taking St John's Wort 7. Patients who have received ECT in the past 1 month prior to intake 8. Patients at ongoing risk for severe substance or alcohol withdrawal related issues (e.g., delirium tremens, severe opiate withdrawal) or who present with substance-induced psychosis 9. Arrested or incarcerated individuals brought in by the legal system for medical stabilization
Study Locations (1)
University of Pittsburgh
Pittsburgh, Pennsylvania, United States